Retatrutide — commonly referred to as "reta" in patient communities — has generated more clinical excitement than nearly any obesity medicine compound in recent memory. As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it works through mechanisms that go well beyond earlier generation weight-loss medications. The Phase 2 trial published in the New England Journal of Medicine in 2023 showed mean weight loss of up to 24.2% at 48 weeks in people without type 2 diabetes. Then came the TRIUMPH-4 Phase 3 press release in December 2025, reporting 28.7% mean weight loss at 68 weeks — the highest figure ever recorded in a Phase 3 obesity trial.
But TRIUMPH-4 is only one piece of a much larger clinical picture. The full TRIUMPH program spans multiple Phase 3 trials examining retatrutide across obesity, type 2 diabetes, cardiovascular disease, and renal endpoints. Understanding what each trial is testing — and when results are expected — is essential context for anyone following retatrutide phase 3 results closely.
TRIUMPH-4 is a 68-week Phase 3 trial that evaluated retatrutide specifically in adults with type 2 diabetes and obesity. This population was explicitly excluded from the Phase 2 obesity trial, making TRIUMPH-4 a critical expansion of what is clinically known about the drug.
The 12mg dose arm achieved 28.7% mean weight loss over 68 weeks — a figure that surpasses tirzepatide's SURMOUNT-1 result of 20.9% at 15mg and semaglutide's STEP-1 result at 68 weeks. Importantly, TRIUMPH-4 also measured glycemic control as a primary objective, meaning HbA1c reduction data is expected alongside the weight loss results.
The titration schedule used in TRIUMPH-4 was gradual by design: 2mg in weeks 1–4, advancing to 4mg, then 6mg, then 9mg, with full 12mg maintenance beginning at week 17. This slow escalation was intended to minimize gastrointestinal side effects — the same nausea, diarrhea, and vomiting that appeared dose-dependently in Phase 2.
Two safety findings from TRIUMPH-4 deserve clinical attention. Discontinuation rates were notably higher in the active arms — 18.2% in the 12mg group versus 4.0% for placebo — with some participants discontinuing due to what investigators described as perceived excessive weight loss. Dysesthesia (abnormal skin sensations) occurred in 20.9% of participants at the 12mg dose versus 0.7% on placebo, a substantially higher rate than the 12.9% observed at the same dose in Phase 2. Full peer-reviewed publication of TRIUMPH-4 data was pending as of April 2026.
TRIUMPH-5 is designed as a dedicated cardiovascular outcomes trial, targeting major adverse cardiovascular events (MACE) in high-risk patients. This class of trial — sometimes called a CVOT — has become a regulatory standard for obesity and diabetes medications since the FDA began requiring cardiovascular safety data for glucose-lowering drugs.
Where TRIUMPH-4 asks "how much weight and glycemic improvement can retatrutide produce in people with type 2 diabetes," TRIUMPH-5 asks a harder question: "Does retatrutide reduce heart attacks, strokes, and cardiovascular death in people already at elevated cardiovascular risk?" Trial enrollment was reported as closed in 2024–2025, with data readouts expected during the 2025–2026 window. Full results, however, had not been publicly released as of April 2026.
The triple agonist mechanism gives TRIUMPH-5 particular scientific interest. The glucagon receptor component of retatrutide has shown effects on lipid metabolism in Phase 2 data — triglycerides fell by 34% at the 12mg dose at 24 weeks — raising the hypothesis that retatrutide may offer cardiovascular benefit beyond weight loss alone.
The TRIUMPH-1 trial retatrutide arm focuses on obesity without type 2 diabetes — essentially a Phase 3 extension of the population studied in Phase 2. Its primary endpoint is percent change in body weight, and it represents the most direct path toward a potential FDA indication for obesity. TRIUMPH-4 and TRIUMPH-5 expand the program into metabolic disease populations where weight loss intersects with serious comorbidity management.
In practical terms: TRIUMPH-1 is the trial most relevant to people pursuing retatrutide for obesity treatment; TRIUMPH-4 is most relevant to people managing weight alongside type 2 diabetes; and TRIUMPH-5 addresses cardiovascular risk reduction as an independent question.
| Trial | Primary Population | Key Endpoints | Duration |
|---|---|---|---|
| TRIUMPH-1 | Obesity, no T2D | % body weight change | Not yet confirmed publicly |
| TRIUMPH-4 | Obesity + type 2 diabetes | % body weight change, HbA1c reduction | 68 weeks |
| TRIUMPH-5 | High cardiovascular risk | MACE (CV death, MI, stroke) | Multi-year (event-driven) |
Across the TRIUMPH program, secondary endpoints include waist circumference reduction, cardiometabolic biomarkers such as triglycerides and LDL cholesterol, quality of life measures, and responder thresholds (≥5%, ≥10%, ≥20% body weight loss). The Phase 2 data showed that at the 8mg dose, 100% of participants achieved at least 5% weight loss at 48 weeks — a benchmark that no prior obesity drug had reached universally in a randomized trial.
The TRIUMPH-4 press release data arrived in December 2025, but peer-reviewed publication had not occurred as of April 2026. Cardiovascular outcomes from TRIUMPH-5 are inherently event-driven and typically require longer follow-up than weight-focused trials, meaning those results are unlikely to arrive before 2026 at the earliest. An NDA (New Drug Application) for retatrutide had not been filed with the FDA as of April 2026, and no confirmed FDA approval timeline has been made public.
For those tracking retatrutide phase 3 results, the most meaningful near-term milestones are the peer-reviewed TRIUMPH-4 publication and any conference presentations from TRIUMPH-1. Major endocrinology and obesity medicine meetings — including ADA, ENDO, and ObesityWeek — are the most likely venues for early data disclosures.
The concept of "food noise" — the persistent, intrusive mental preoccupation with food that makes weight management feel psychologically exhausting — has become a central part of how patients describe their experience with GLP-1 and triple agonist therapies. If TRIUMPH-4's 28.7% weight loss figure holds up in peer review, and if TRIUMPH-5 demonstrates cardiovascular benefit, retatrutide could represent a meaningful step forward not just in numbers on a scale, but in the underlying biology of chronic weight management.
glp3md maintains an active waitlist for individuals who want to stay informed as retatrutide phase 3 results continue to emerge. Joining the waitlist at https://www.glp3md.com provides access to clinical updates, trial summaries, and information about retatrutide's regulatory progress as it becomes available. Retatrutide is not FDA-approved, and joining the waitlist does not guarantee access to medication, treatment, or a prescription of any kind. It is an informational resource for people who want to follow this science closely and be among the first to know when the landscape changes.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.